WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001068077) IMMUNOSTIMULATORY POLYNUCLEOTIDE SEQUENCES FOR USE IN PREVENTING AND TREATING VIRAL INFECTIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/068077    International Application No.:    PCT/US2001/007840
Publication Date: 20.09.2001 International Filing Date: 12.03.2001
Chapter 2 Demand Filed:    10.10.2001    
IPC:
A61K 31/7105 (2006.01), C12N 15/11 (2006.01)
Applicants: DYNAVAX TECHNOLOGIES CORPORATION [US/US]; Suite 100, 717 Potter Street, Berkeley, CA 94710 (US) (For All Designated States Except US).
VAN NEST, Gary [US/US]; (US) (For US Only).
EIDEN, Joseph, J., Jr. [US/US]; (US) (For US Only)
Inventors: VAN NEST, Gary; (US).
EIDEN, Joseph, J., Jr.; (US)
Agent: ZACHOW, Karen, R.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).
GOLDIN, Douglas, Michael; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB)
Priority Data:
60/188,302 10.03.2000 US
09/802,685 09.03.2001 US
Title (EN) IMMUNOSTIMULATORY POLYNUCLEOTIDE SEQUENCES FOR USE IN PREVENTING AND TREATING VIRAL INFECTIONS
(FR) PREVENTION ET TRAITEMENT D'INFECTIONS VIRALES AU MOYEN DE SEQUENCES POLYNUCLEOTIDIQUES IMMUNOMODULATOIRES
Abstract: front page image
(EN)The invention provides methods of suppression, prevention, and/or treatment of infection by viruses. A polynucleotide comprising an immunostimulatory sequence (an 'ISS') is administered to an individual who is at risk of being exposed to, has been exposed to or is infected with a virus. The ISS-containing polynucleotide is administered without any antigens of the virus. Administration of the ISS-containing polynucleotide results in reduced incidence and/or severity of one or more symptoms of virus infection.
(FR)Cette invention concerne des méthodes destinées à supprimer, prévenir et/ou traiter des infections virales. A un individu qui risque d'être exposé, a été exposé ou est infecté par un virus, on administre un polynucléotide renfermant une séquence immunostimulatoire. Le polynucléotide qui renferme ladite séquence est administré sans antigène du virus. L'administration de cette séquence polynucléotidique immunomodulatoire se traduit par une baisse de l'incidence et/ou une moindre gravité de l'un ou de plusieurs symptômes de l'affection virale.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)